Compare
Ardelyx, Inc. vs Innoviva, Inc. vs Sinovac Biotech Ltd vs Arcutis Biotherapeutics, Inc.
| Latest fiscal year | Ardelyx, Inc. ARDX | Innoviva, Inc. INVA | Sinovac Biotech Ltd SVA | Arcutis Biotherapeutics, Inc. ARQT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $407.32M | $411.33M | $386.01M | $372.07M |
| Revenue growth (YoY) | +22.1% | +14.7% | +6.8% | +123.4% |
| Gross margin | 90.3% (computed) | 74.8% | 67.9% | 90.1% (computed) |
| Operating margin | -10.1% | 39.8% | -127.0% | -3.3% |
| Net margin | -15.1% | 65.9% | -51.5% | -4.3% |
| Net income | -$61.60M | $271.17M | -$198.84M | -$16.14M |
| EPS (Diluted) | -$0.26 | $3.30 | -$0.83 | -$0.13 |
| Operating cash flow | -$42.48M | $196.93M | -$512.18M | -$5.62M |
| Free cash flow | -$43.98M | $195.80M | -$561.10M | -$6.31M |
| Cash & equivalents | $68.00M | $550.94M | $488.25M | $42.91M |
| Total assets | $501.60M | $1.64B | $8.54B | $432.97M |
| Total liabilities | $334.65M | n/a | $2.15B | $243.49M |
| Shareholders' equity | $166.95M | $1.17B | $6.40B | $189.48M |
| Return on year-end equity | -36.9% | 23.1% | -3.1% | -8.5% |
| Shares outstanding | 244.35M | 74.64M | 71.86M | 123.33M |
Revenue, most recent five fiscal years
| Fiscal year | Ardelyx, Inc. | Innoviva, Inc. | Sinovac Biotech Ltd | Arcutis Biotherapeutics, Inc. |
|---|---|---|---|---|
| Latest | $407.32M Ended 2025-12-31 | $411.33M Ended 2025-12-31 | $386.01M Ended 2025-12-31 | $372.07M Ended 2025-12-31 |
| 1 year earlier | $333.62M Ended 2024-12-31 | $358.71M Ended 2024-12-31 | $361.37M Ended 2024-12-31 | $166.54M Ended 2024-12-31 |
| 2 years earlier | $124.46M Ended 2023-12-31 | $310.46M Ended 2023-12-31 | $470.17M Ended 2023-12-31 | $59.61M Ended 2023-12-31 |
| 3 years earlier | $52.16M Ended 2022-12-31 | $331.34M Ended 2022-12-31 | $1.47B Ended 2022-12-31 | $3.69M Ended 2022-12-31 |
| 4 years earlier | $10.10M Ended 2021-12-31 | $391.87M Ended 2021-12-31 | $19.37B Ended 2021-12-31 | $0 Ended 2021-12-31 |